Natural killer (NK) cell therapy is a growing area of research that concentrates on modifying the framework of NK cells to combat development of certain conditions. Paul Y Song, MD, NKGen Biotech, Santa Ana, CA, has been developing a unique autologous NK cell product called SNK01, which aims to treat patients with Alzheimer’s Disease (AD), focusing on the clearance of protein accumulation and improving cognitive functioning. Here, Dr Song talks about the current areas of research within NK therapies. While Dr Songs’ current research primarily focuses on the use of NK cells within AD, he discusses how NK cells could be used for other conditions such as Parkinson’s disease and other neurological diseases associated with neuroinflammation. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
